Agilent Technologies (A)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
$131.13+0.41%
Close 2026-07-07 · 1-day change
Reading A? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track A free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
Reading A? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track A free→QuarterlyIQ Insights · A
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-07-07.
The screen ranks A against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Met or beat guidance 88% of the last 8 guided quarters · 3.0% avg surprise
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 50% of the time over the next year (vs 42% for the rest of the cohort, n=9129).
Over the trailing year it converted 1.03x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 29% of the time over the next year (vs 51% for the rest of the cohort, n=2357).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to real (inflation-adjusted) rates, long-term interest rates, the US dollar, Fed net liquidity (low R² over the window).
16 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 49% of the time over the next year (vs 48% for the rest of the cohort, n=3770).
Not investment advice. As of 2026-07-07.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.